View Older Stories View More Recent Stories

Nov 11, 2024 08:40AM Bristol-Myers Squibb (BMY) Climbs 10% After AbbVie's Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint

Nov 11, 2024 08:36AM AbbVie (ABBV) Falls 13% After Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint

Nov 11, 2024 08:35AM AbbVie (ABBV) Phase 2 Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint

Oct 31, 2024 08:14AM Abbvie (ABBV) PT Raised to $228 at BMO Capital

Oct 31, 2024 08:02AM AbbVie (ABBV), EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

Oct 30, 2024 07:39AM AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance

Oct 29, 2024 11:20AM AbbVie (ABBV) January 185 calls active into quarter results

Oct 28, 2024 08:01AM AbbVie (ABBV) Acquires Aliada Therapeutics

Oct 24, 2024 11:32AM AbbVie (ABBV) and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions

Oct 18, 2024 05:50AM Abbvie (ABBV) PT Raised to $195 at BofA Securities

Oct 17, 2024 08:03AM AbbVie (ABBV): U.S. FDA Approves VYALEV for Adults Living with Advanced Parkinson's Disease

Oct 16, 2024 11:00AM This pharma stock could deliver a beat and raise quarter, according to Wells Fargo

Oct 10, 2024 07:06AM Abbvie (ABBV) PT Raised to $215 at Truist Securities

Oct 7, 2024 09:23AM Abbvie (ABBV) PT Raised to $225 at TD Cowen

Oct 3, 2024 04:13PM AbbVie (ABBV) says earnings will include acquired IPR&D and milestones expense of $82 million on a pre-tax basis

Oct 3, 2024 04:09PM Morgan Stanley Reiterates Overweight Rating on Abbvie (ABBV)

Sep 27, 2024 12:17PM AbbVie (ABBV) Submits Biologics License Application to the FDA for Telisotuzumab Vedotin

Sep 26, 2024 12:13PM BMO Capital Reiterates Outperform Rating on Abbvie (ABBV)

Sep 26, 2024 08:00AM AbbVie (ABBV) Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

Sep 25, 2024 07:01AM AbbVie (ABBV): New Analysis Demonstrates the Efficacy of RINVOQ in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement

Sep 24, 2024 07:42AM Piper Sandler Reiterates Overweight Rating on Abbvie (ABBV)

Sep 20, 2024 07:33AM AbbVie (ABBV) Receives Positive CHMP Opinion for Mirvetuximab Soravtansine for the Treatment of Certain Adult Ovarian Cancer

Sep 17, 2024 02:00PM JPMorgan refreshed its U.S. Analyst Focus List and added these four names

Sep 11, 2024 08:31AM AbbVie's (ABBV) Allergan Aesthetics Launches BOTOX Cosmetic for Masseter Muscle Prominence in Adults in China

Sep 10, 2024 12:23PM Unitedhealth Says It Will Remove Abbvie's (ABBV) Humira From Some U.S. Drug Reimbursement Lists Next Year - Reuters

Sep 6, 2024 10:19AM AbbVie (ABBV) Maintains Quarterly Dividend at $1.55; 3.2% Yield

Sep 6, 2024 09:59AM Deutsche Bank on Abbvie (ABBV): 'IMS/IQVIA data for the week ending 8/30/24 show branded Humira holding at 69.6% share (-0.8% w/w) of Adalimumab scripts'

Sep 3, 2024 05:45AM Deutsche Bank Reiterates Hold Rating on Abbvie (ABBV)

Aug 27, 2024 08:07AM AbbVie (ABBV): SkinMedica Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator

Aug 23, 2024 08:33AM Abbvie (ABBV) PT Raised to $209 at Piper Sandler

Aug 19, 2024 02:06PM AbbVie (ABBV): EC Grants Second Indication Approval for TEPKINLY for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Aug 15, 2024 07:56AM Stifel Reiterates Buy Rating on Vigil Neuroscience Inc (VIGL)

Aug 12, 2024 10:00AM Morgan Stanley has just added these three stocks to its Fresh Money Buy List

Aug 1, 2024 08:24AM AbbVie (ABBV) Completes Acquisition of Cerevel Therapeutics

Jul 26, 2024 06:39AM AbbVie (ABBV) Announces European Commission Approval of SKYRIZI for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Jul 26, 2024 05:53AM Abbvie (ABBV) PT Raised to $200 at Goldman Sachs

Jul 26, 2024 05:37AM William Blair Reiterates Outperform Rating on Abbvie (ABBV)

Jul 25, 2024 04:12PM Abbvie (ABBV) PT Raised to $210 at Truist Securities

Jul 25, 2024 03:56PM Abbvie (ABBV) PT Raised to $210 at JPMorgan

Jul 25, 2024 07:56AM AbbVie hikes full-year earnings guidance as Humira sales top estimates

Jul 25, 2024 07:50AM AbbVie (ABBV) Misses Q2 EPS by 5c; offers guidance

Jul 25, 2024 05:17AM Stocks expected to have increasing option volume: ABBV TRU HAS KDP LUV WH IBM CMG NOW LVS

Jul 24, 2024 11:21AM AbbVie (ABBV) call put ratio 1 call to 1 put into quarter results

Jul 24, 2024 04:42AM AbbVie (ABBV) July weekly 172.50 straddle priced into quarter results

Jul 19, 2024 08:55AM Abbvie (ABBV) PT Raised to $214 at BMO Capital

Jul 12, 2024 08:31AM AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Upadacitinib in Giant Cell Arteritis

Jul 10, 2024 08:00AM AbbVie (ABBV) Appoints Roopal Thakkar as and Chief Scientific Officer

Jul 3, 2024 05:21AM AbbVie (ABBV) option IV flat into 2024 USA elections

Jul 2, 2024 07:23AM Piper Sandler Reiterates Overweight Rating on Abbvie (ABBV)

Jul 1, 2024 08:00AM AbbVie (ABBV) Appoints Robert A. Michael as CEO

View More Recent Stories View Older Stories